Cerebroprotective effect of sitagliptin and aminoguanidine combination in disorders of cerebral circulation

The aim of the study was to evaluate a cerebroprotective activity of the sitagliptin and aminoguanidine combination in rats with an acute and chronic cerebral circulation insufficiency, as well as with a traumatic brain injury.

Materials and methods. The study was carried out on male Wistar rats in 3 stages using, respectively, a model of a chronic pathology: a chronic cerebral circulation insufficiency (CCCI), as well as 2 models of the acute brain injury (BI): an acute cerebral circulation insufficiency (ACCI), and a traumatic brain injury (TBI). А CCCI was modeled by a bilateral stenosis of the common carotid arteries (by 50%), a model of a hemorrhagic stroke caused by an intracerebral injection of the autologous blood was used as a stroke, a TBI was modeled by a mechanical damage to the brain tissue. To assess the pathology course severity, the following tests were used: Adhesion test, Open field, Morris water maze test, as well as Garcia and Combs&D’Alecy scales. In the animals with an acute damage to the brain at the end of the experiment, the severity of edema of the affected hemisphere was also determined. The treatment was with sitagliptin (10 mg/kg), aminoguanidine (25 mg/kg), or a combination thereof. The obtained data were subjected to the statistical processing.

Results. In the course of the study, it was found out that the administration of a sitagliptin and aminoguanidine combination, unlike each of the components, had a cerebroprotective effect in the animals with a chronic or acute damage to the brain, reducing the severity of psychoneurological (cognitive and sensory-motor) disorders, as well as the brain edema.

Conclusion. Aminoguanidine, as an iNOS blocker, enhances the action of sitagliptin, preventing the brain edema development and reducing the neurological deficit severity (the severity of cognitive and sensory-motor impairments) in the animals with an acute and chronic cerebral circulation insufficiency.

1. Soloveva EYu, Amelina IP. Cerebral small vessel disease’s impact on the development of chronic cerebral ischemia: paradigms of treatment. Medical Council. 2020;(2):16–24. DOI: 10.21518/2079-701X-2020-2-16-24. Russian

2. Machinskiy PA, Plotnikova NA, Ul’yankin VE, Kemaykin SP, Rybakov AG. Comparative characteristics of the indicators of mortality and letality from ischemic and hemorrhagic insult in Russia. University proceedings. Volga region. Medical sciences. 2019;3(51):101–18. DOI: 10.21685/2072-3032-2019-3-10. Russian

3. Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA, Barker-Collo S, Moran AE, Sacco RL, Truelsen T, Davis S, Pandian JD, Naghavi M, Forouzanfar MH, Nguyen G, Johnson CO, Vos T, Meretoja A, Murray CJ, Roth GA; GBD 2013 Writing Group; GBD 2013 Stroke Panel Experts Group. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology. 2015;45(3):161–76. DOI: 10.1159/000441085

4. Voronina VP, Zagrebelnyi AV, Lukina YuV, Kutishenko NP, Dmitrieva NA, Lerman OV, Lukyanov MM, Okshina ЕYu, Blagodatskikh SV, Ivanova LP, Boytsov SА, Drapkina OM, Martsevich SYu. Features of cerebral stroke course in patients with diabetes mellitus according to the REGION-M register. Cardiovascular Therapy and Prevention. 2019;18(5):60–5. DOI: 10.15829/1728-8800-2019-5-60-65. Russian

5. Galgano M, Toshkezi G, Qiu X, Russell T, Chin L, Zhao LR. Traumatic Brain Injury: Current Treatment Strategies and Future Endeavors. Cell Transplant. 2017 Jul;26(7):1118–30. DOI: 10.1177/0963689717714102

6. Lustenberger T, Talving P, Lam L, Inaba K, Bass M, Plurad D, Demetriades D. Effect of diabetes mellitus on outcome in patients with traumatic brain injury: a national trauma databank analysis. Brain Inj. 2013;27(3):281–5. DOI: 10.3109/02699052.2012.743178

7. Ametov AS, Nevolnikova AO, Tertychnaya EA. The potential of GLP-1 receptor agonists in reducing cardiovascular risk in patients with type 2 diabetes mellitus: what’s new? Endocrinology: News, Opinions, Training. 2019;8(3):44–53. DOI: 10.24411/2304-9529-2019-13005. Russian

8. Tyurenkov IN, Bakulin DA, Kurkin DV, Volotova EV. Neuroprotective properties of incretin mimetics in brain ischemia and neurodegenerative diseases. Problems of Endocrinology. 2017;63(1):58–67. DOI: 10.14341/probl201763158-67

9. Kurkin DV, Bakulin DA, Morkovin EI, Strygin AV, Gorbunova YuV, Volotova EV, Makarenko IE, Saparova VB, Drai RV, Petrov VI. Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use. Pharmacy & Pharmacology. 2023;11(1):19–47. DOI: 10.19163/2307-9266-2023-11-1-19-47

10. Kurkin DV, Abrosimova EE, Bakulin DA, Kovalev NS, Dubrovina MA, Borisov AV, Strygin AV, Morkovin EI, Tyurenkov IN. Activity modulation of various nitric oxide syntases as an approach to endothelial dysfunction therapy. Pharmacy & Pharmacology. 2022;10(2):130–53. DOI: 10.19163/2307-9266-2022-10-2-130-153

11. Vakili A, Zahedi-Khorasani M. Effect of aminoguanidine on post-ischemic damage in rodent model of stroke. Pak J Pharm Sci. 2008 Jan;21(1):24-8.

12. Vakili A, Hosseinzadeh F, Sadogh T. Effect of aminoguanidine on post-ischemic brain edema in transient model of focal cerebral ischemia. Brain Res. 2007 Sep 19;1170:97–102. DOI: 10.1016/j.brainres.2007.07.016

13. Pérez-Asensio FJ, Hurtado O, Burguete MC, Moro MA, Salom JB, Lizasoain I, Torregrosa G, Leza JC, Alborch E, Castillo J, Knowles RG, Lorenzo P. Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorates stroke outcome after experimental ischemia. Neurobiol Dis. 2005 Mar;18(2):375–84. DOI: 10.1016/j.nbd.2004.10.018

14. Sugimoto K, Iadecola C. Effects of aminoguanidine on cerebral ischemia in mice: comparison between mice with and without inducible nitric oxide synthase gene. Neurosci Lett. 2002 Oct 4;331(1):25–8. DOI: 10.1016/s0304-3940(02)00834-0

15. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys. 2003 Nov 1;419(1):31–40. DOI: 10.1016/j.abb.2003.08.013

16. Kurkin DV, Morkovin EI, Verkholyak DV, Bakulin DA, Volotova EV, Tyurenkov IN. Changes in cerebral blood flow in rats with experimental stenosis of common carotid arteries. Journal of Volgograd State Medical University. 2017;1(61):36–9. Russian

17. Wu G, Bao X, Xi G, Keep RF, Thompson BG, Hua Y. Brain injury after intracerebral hemorrhage in spontaneously hypertensive rats. J Neurosurg. 2011 Jun;114(6):1805–11. DOI: 10.3171/2011.1.JNS101530

18. Kurkin DV, Bakulin DA, Morkovin EI, Kalatanova AV, Makarenko IE, Dorotenko AR, Kovalev NS, Dubrovina MA, Verkholyak DV, Abrosimova EE, Smirnov AV, Shmidt MV, Tyurenkov IN. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One. 2021 Jul 14;16(7):e0254493. DOI: 10.1371/journal.pone.0254493

19. Dayneko AS, Shmonin AA, Shumeeva AV, Kovalenko EA, Melnikova EV, Vlasov TD. Assessment of neurological deficit in the early and late phase after a 30-minute of focal cerebral ischemia in rats. Regional blood circulation and microcirculation. 2014;13(1):68–78. DOI: 10.24884/1682-6655-2014-13-1-68-78. Russian

20. Bouet V, Boulouard M, Toutain J, Divoux D, Bernaudin M, Schumann-Bard P, Freret T. The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat Protoc. 2009;4(10):1560–4. DOI: 10.1038/nprot.2009.125

21. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1(2):848-58. DOI: 10.1038/nprot.2006.116

22. Han W, Li Y, Cheng J, Zhang J, Chen D, Fang M, Xiang G, Wu Y, Zhang H, Xu K, Wang H, Xie L, Xiao J. Sitagliptin improves functional recovery via GLP-1R-induced anti-apoptosis and facilitation of axonal regeneration after spinal cord injury. J Cell Mol Med. 2020 Aug;24(15):8687–702. DOI: 10.1111/jcmm.15501

23. Sugimoto K, Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. Microvasc Res. 1997 Mar;53(2):105–12. DOI: 10.1006/mvre.1996.2002

24. Ametov AS, Kamynina LL, Akhmedova ZG. Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists. Kardiologiia 2014;54(7):92–6. DOI: 10.18565/cardio.2014.7.92-96